EN | SE Contact us Careers


Nov 8-15, 2021 LSX Investival Showcase

Nov 11, 2021, Redeye Life Science Day, Stockholm, Sweden

Nov 16-22, 2021, Jefferies London Healthcare Conference, London, UK

Other news

CEO Martin Welschof presents at the Redeye Life Science Day. Nov 11, 2021 > Link

BioInvent Q3 2021 report audiocast > Link
Slide deck > Link

BioInvent CEO on the benefits of a diversified portfolio. > Link

1907 FP Imonc


BioInvent’s primary goal is to develop next generation immuno-oncology drugs with a focus on improving therapeutic results in areas with significant unmet need.

Read More


BioInvent Fast Facts




BioInvent’s strategy is to leverage its expertise in immunology, cancer biology and antibody biology to develop cancer immunotherapies to improve the quality of life for cancer patients. This is accomplished through collaborations with pharmaceutical companies, academic research groups, networks of clinical specialists and research foundations. The goal is to create value for the Company’s shareholders based on successful drug development and subsequent revenue streams from existing and future commercial partners.

Read More

Our tools for successful drug development



In an automated process, we select optimal antibodies for new drug candidates from our own antibody library – one of the largest in the world.


Our unique and patented screening-platform has the advantage of simultaneously identifying disease-associated targets and antibodies that bind to them.


Our cGMP certified manufacturing site provides antibodies for in-house project development, as well as for external customers.


  • +/-
  • +/-
  • Opening price
  • Bid
  • Ask
  • High
  • Low
  • Volume
  • Turnover
  • Updated